Atlas Trials

Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Clinical trial NCT05446831 · UNKNOWN

Trial details

NCT number
NCT05446831
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
ITPImmune Thrombocytopenia
Start date
2022-07-13
Primary completion
2023-06-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.